Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

(2020) P. Schmid et al.   ANNALS OF ONCOLOGY

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

(2020) Rita Nanda et al.   JAMA Oncology

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

(2019) Emina Torlakovic et al.   MODERN PATHOLOGY

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

(2018) Bharathi Vennapusa et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

(2018) Leisha A. Emens et al.   JAMA Oncology

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple Testing in Group Sequential Trials Using Graphical Approaches

(2013) Willi Maurer et al.   Statistics in Biopharmaceutical Research

Triple-negative breast cancer: are we making headway at least?

(2012) Monica Arnedos et al.   Therapeutic Advances in Medical Oncology

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

(2010) Rupal Ramakrishnan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Regulation of Cancer

(2010) Mary L. Disis   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design

(2009) Farrah Kassam et al.   Clinical Breast Cancer

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Pattern of metastatic spread in triple-negative breast cancer

(2008) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER